Ryancoates (Talk | contribs) |
|||
Line 14: | Line 14: | ||
<th>Coding sequence</th> | <th>Coding sequence</th> | ||
<th>Terminator</th> | <th>Terminator</th> | ||
− | <th>Plasmid</th> | + | <th>Plasmid backbone</th> |
<th>Summary</th> | <th>Summary</th> | ||
<th>Approximate Length</th> | <th>Approximate Length</th> | ||
Line 23: | Line 23: | ||
<td>TSH</td> | <td>TSH</td> | ||
<td>NosT</td> | <td>NosT</td> | ||
− | <td>pGB-A2</td> | + | <td><a href="http://parts.igem.org/Part:BBa_P10503">pGB-A2</a></td> |
<td>A constitutive promoter with our TSH antagonist <b>without</b> the his tags for purification</td> | <td>A constitutive promoter with our TSH antagonist <b>without</b> the his tags for purification</td> | ||
<td>~length</td> | <td>~length</td> | ||
Line 31: | Line 31: | ||
<td>TSHH</td> | <td>TSHH</td> | ||
<td>NosT</td> | <td>NosT</td> | ||
− | <td>pGB-A2</td> | + | <td><a href="http://parts.igem.org/Part:BBa_P10503">pGB-A2</a></td> |
<td>A constitutive promoter with our TSH antagonist <b>with</b> the his tags for purification</td> | <td>A constitutive promoter with our TSH antagonist <b>with</b> the his tags for purification</td> | ||
<td>~length</td> | <td>~length</td> | ||
Line 39: | Line 39: | ||
<td>Luc+</td> | <td>Luc+</td> | ||
<td>NosT</td> | <td>NosT</td> | ||
− | <td>pGB-A2</td> | + | <td><a href="http://parts.igem.org/Part:BBa_P10503">pGB-A2</a></td> |
<td>A constitutive promoter with Luc+ as a coding sequence to analyse expression levels</td> | <td>A constitutive promoter with Luc+ as a coding sequence to analyse expression levels</td> | ||
<td>~length</td> | <td>~length</td> | ||
Line 47: | Line 47: | ||
<td>Lucx5</td> | <td>Lucx5</td> | ||
<td>NosT</td> | <td>NosT</td> | ||
− | <td>pGB-A2</td> | + | <td><a href="http://parts.igem.org/Part:BBa_P10503">pGB-A2</a></td> |
<td>A constitutive promoter with Lucx5 as a coding sequence to analyse expression levels. This variant is heat resistant</td> | <td>A constitutive promoter with Lucx5 as a coding sequence to analyse expression levels. This variant is heat resistant</td> | ||
<td>~length</td> | <td>~length</td> | ||
Line 55: | Line 55: | ||
<td>XVE</td> | <td>XVE</td> | ||
<td>NosT</td> | <td>NosT</td> | ||
− | <td>pGB-A2</td> | + | <td><a href="http://parts.igem.org/Part:BBa_P10503">pGB-A2</a></td> |
<td>A constitutive promoter with XVE as a coding sequence. This produces a protein product that activates the inducible promoter LexA</td> | <td>A constitutive promoter with XVE as a coding sequence. This produces a protein product that activates the inducible promoter LexA</td> | ||
<td>~length</td> | <td>~length</td> | ||
Line 63: | Line 63: | ||
<td>TSH</td> | <td>TSH</td> | ||
<td>NosT</td> | <td>NosT</td> | ||
− | <td>pGB-A2</td> | + | <td><a href="http://parts.igem.org/Part:BBa_P10503">pGB-A2</a></td> |
<td>A promoter that is induced by XVE with our TSH antagonist <b>without</b> the his tags for purification</td> | <td>A promoter that is induced by XVE with our TSH antagonist <b>without</b> the his tags for purification</td> | ||
<td>~length</td> | <td>~length</td> | ||
Line 71: | Line 71: | ||
<td>TSHH</td> | <td>TSHH</td> | ||
<td>NosT</td> | <td>NosT</td> | ||
− | <td>pGB-A2</td> | + | <td><a href="http://parts.igem.org/Part:BBa_P10503">pGB-A2</a></td> |
<td>A promoter that is induced by XVE with our TSH antagonist <b>with</b> the his tags for purification</td> | <td>A promoter that is induced by XVE with our TSH antagonist <b>with</b> the his tags for purification</td> | ||
<td>~length</td> | <td>~length</td> | ||
Line 79: | Line 79: | ||
<td>Luc+</td> | <td>Luc+</td> | ||
<td>NosT</td> | <td>NosT</td> | ||
− | <td>pGB-A2</td> | + | <td><a href="http://parts.igem.org/Part:BBa_P10503">pGB-A2</a></td> |
<td>A promoter that is induced by XVE with Luc+ as a coding sequence to analyse expression levels</td> | <td>A promoter that is induced by XVE with Luc+ as a coding sequence to analyse expression levels</td> | ||
<td>~length</td> | <td>~length</td> | ||
Line 87: | Line 87: | ||
<td>Lucx5</td> | <td>Lucx5</td> | ||
<td>NosT</td> | <td>NosT</td> | ||
− | <td>pGB-A2</td> | + | <td><a href="http://parts.igem.org/Part:BBa_P10503">pGB-A2</a></td> |
<td>A promoter that is induced by XVE with Lucx5 as a coding sequence to analyse expression levels. This variant is heat resistant</td> | <td>A promoter that is induced by XVE with Lucx5 as a coding sequence to analyse expression levels. This variant is heat resistant</td> | ||
<td>~length</td> | <td>~length</td> | ||
Line 95: | Line 95: | ||
<td>TSH</td> | <td>TSH</td> | ||
<td>NosT</td> | <td>NosT</td> | ||
− | <td>pGB-A2</td> | + | <td><a href="http://parts.igem.org/Part:BBa_P10503">pGB-A2</a></td> |
<td>A promoter induced by jasmonic acid with our TSH antagonist <b>without</b> the his tags for purification</td> | <td>A promoter induced by jasmonic acid with our TSH antagonist <b>without</b> the his tags for purification</td> | ||
<td>~length</td> | <td>~length</td> | ||
Line 104: | Line 104: | ||
<td>TSHH</td> | <td>TSHH</td> | ||
<td>NosT</td> | <td>NosT</td> | ||
− | <td>pGB-A2</td> | + | <td><a href="http://parts.igem.org/Part:BBa_P10503">pGB-A2</a></td> |
<td>A promoter induced by jasmonic acid with our TSH antagonist <b>with</b> the his tags for purification</td> | <td>A promoter induced by jasmonic acid with our TSH antagonist <b>with</b> the his tags for purification</td> | ||
<td>~length</td> | <td>~length</td> | ||
Line 112: | Line 112: | ||
<td>Luc+</td> | <td>Luc+</td> | ||
<td>NosT</td> | <td>NosT</td> | ||
− | <td>pGB-A2</td> | + | <td><a href="http://parts.igem.org/Part:BBa_P10503">pGB-A2</a></td> |
<td>A promoter induced by jasmonic acid with Luc+ as a coding sequence to analyse expression levels</td> | <td>A promoter induced by jasmonic acid with Luc+ as a coding sequence to analyse expression levels</td> | ||
<td>~length</td> | <td>~length</td> | ||
Line 120: | Line 120: | ||
<td>TSH</td> | <td>TSH</td> | ||
<td>NosT</td> | <td>NosT</td> | ||
− | <td>pGB-A2</td> | + | <td><a href="http://parts.igem.org/Part:BBa_P10503">pGB-A2</a></td> |
<td>A promoter induced by salicylic acid with our TSH antagonist <b>without</b> the his tags for purification</td> | <td>A promoter induced by salicylic acid with our TSH antagonist <b>without</b> the his tags for purification</td> | ||
<td>~length</td> | <td>~length</td> | ||
Line 128: | Line 128: | ||
<td>TSHH</td> | <td>TSHH</td> | ||
<td>NosT</td> | <td>NosT</td> | ||
− | <td>pGB-A2</td> | + | <td><a href="http://parts.igem.org/Part:BBa_P10503">pGB-A2</a></td> |
<td>A promoter induced by salicylic acid with our TSH antagonist <b>with</b> the his tags for purification</td> | <td>A promoter induced by salicylic acid with our TSH antagonist <b>with</b> the his tags for purification</td> | ||
<td>~length</td> | <td>~length</td> | ||
Line 136: | Line 136: | ||
<td>Luc+</td> | <td>Luc+</td> | ||
<td>NosT</td> | <td>NosT</td> | ||
− | <td>pGB-A2</td> | + | <td><a href="http://parts.igem.org/Part:BBa_P10503">pGB-A2</a></td> |
<td>A promoter induced by salicylic acid with Luc+ as a coding sequence to analyse expression levels</td> | <td>A promoter induced by salicylic acid with Luc+ as a coding sequence to analyse expression levels</td> | ||
<td>~length</td> | <td>~length</td> | ||
Line 144: | Line 144: | ||
<td>TSH</td> | <td>TSH</td> | ||
<td>NosT</td> | <td>NosT</td> | ||
− | <td>pGB-A2</td> | + | <td><a href="http://parts.igem.org/Part:BBa_P10503">pGB-A2</a></td> |
<td>A promoter induced by salicylic acid with our TSH antagonist <b>without</b> the his tags for purification</td> | <td>A promoter induced by salicylic acid with our TSH antagonist <b>without</b> the his tags for purification</td> | ||
<td>~length</td> | <td>~length</td> | ||
Line 152: | Line 152: | ||
<td>TSHH</td> | <td>TSHH</td> | ||
<td>NosT</td> | <td>NosT</td> | ||
− | <td>pGB-A2</td> | + | <td><a href="http://parts.igem.org/Part:BBa_P10503">pGB-A2</a></td> |
<td>A promoter induced by salicylic acid with our TSH antagonist <b>with</b> the his tags for purification</td> | <td>A promoter induced by salicylic acid with our TSH antagonist <b>with</b> the his tags for purification</td> | ||
<td>~length</td> | <td>~length</td> | ||
Line 160: | Line 160: | ||
<td>Luc+</td> | <td>Luc+</td> | ||
<td>NosT</td> | <td>NosT</td> | ||
− | <td>pGB-A2</td> | + | <td><a href="http://parts.igem.org/Part:BBa_P10503">pGB-A2</a></td> |
<td>A promoter induced by salicylic acid with Luc+ as a coding sequence to analyse expression levels</td> | <td>A promoter induced by salicylic acid with Luc+ as a coding sequence to analyse expression levels</td> | ||
<td>~length</td> | <td>~length</td> | ||
Line 168: | Line 168: | ||
<td>TSH</td> | <td>TSH</td> | ||
<td>NosT</td> | <td>NosT</td> | ||
− | <td>pGB-A2</td> | + | <td><a href="http://parts.igem.org/Part:BBa_P10503">pGB-A2</a></td> |
<td>A promoter induced by the presence of cellulose (DAMP response) with our TSH antagonist <b>without</b> the his tags for purification</td> | <td>A promoter induced by the presence of cellulose (DAMP response) with our TSH antagonist <b>without</b> the his tags for purification</td> | ||
<td>~length</td> | <td>~length</td> | ||
Line 176: | Line 176: | ||
<td>TSHH</td> | <td>TSHH</td> | ||
<td>NosT</td> | <td>NosT</td> | ||
− | <td>pGB-A2</td> | + | <td><a href="http://parts.igem.org/Part:BBa_P10503">pGB-A2</a></td> |
<td>A promoter induced by the presence of cellulose (DAMP response) with our TSH antagonist <b>with</b> the his tags for purification</td> | <td>A promoter induced by the presence of cellulose (DAMP response) with our TSH antagonist <b>with</b> the his tags for purification</td> | ||
<td>~length</td> | <td>~length</td> | ||
Line 184: | Line 184: | ||
<td>Luc+</td> | <td>Luc+</td> | ||
<td>NosT</td> | <td>NosT</td> | ||
− | <td>pGB-A2</td> | + | <td><a href="http://parts.igem.org/Part:BBa_P10503">pGB-A2</a></td> |
<td>A promoter induced by the presence of cellulose (DAMP response) with Luc+ as a coding sequence to analyse expression levels</td> | <td>A promoter induced by the presence of cellulose (DAMP response) with Luc+ as a coding sequence to analyse expression levels</td> | ||
<td>~length</td> | <td>~length</td> |
Revision as of 18:51, 29 September 2017